Tag: Novartis

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market cap and sales.

Novartis Presented Positive Results from Phase III Study of Jakavi®

Novartis announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-host disease (GvHD). The study met i...

Cosentyx® Treatment Results Show Sustained Improvement in Symptoms of Psoriatic Arthritis

Novartis, a leader in rheumatology and immuno-dermatology, announced results for Cosentyx from a pooled-analysis that shows sustained improvement in signs and symptoms of psoriatic arthritis, particul...

Novartis Confirm High Efficacy and Favorable Safety Profile of Cosentyx®

clinical-trial
Novartis real-world evidence confirms high efficacy, long-term response and favorable safety profile of Cosentyx® in clinical practice. Data from five real-world evidence (RWE) and observational st...

FDA Approved Beovu® Injection

Novartis announced that the U.S. Food and Drug Administration (FDA) approved Beovu® (brolucizumab) injection, also known as RTH258 for the treatment of wet age-related macular degeneration (AMD). Beov...

Novartis Announce Positive Results of Lugelizumab Trials

clinical trials
Novartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mg. Results from a Phase IIb dose-finding study show an avera...

Novartis Announce Positive Results of Cosentyx® Study

clinical-trial
Novartis, a leader in rheumatology and immuno-dermatology, announced additional positive data from the PREVENT trial, evaluating the efficacy and safety of Cosentyx® (secukinumab) in patients with non...

Novartis and Microsoft Agreed to Develop Medicine with Artificial Intelligence

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort. The new...

Once-daily QVM149 Demonstrated Statistically Significant Improvement in Lung Function

novartis
Novartis announced that investigational, once-daily, inhaled QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate or IND/GLY/MF) was superior to QMF149 (indacaterol acetate and m...

Novartis Blamed Former AveXis Executives for Manipulation of Data with Zolgensma

Novartis is blaming former AveXis chief scientific officer Brian Kaspar and senior vice president of R&D Allan Kaspar for the manipulation of data behind its $2.1-million spinal muscular atrophy g...

Novartis’ MS Treatment Met Endpoints in Two Studies

Novartis’ ofatumumab (OMB157) has achieved the primary endpoints in two phase III trials of relapsing multiple sclerosis (MS). The data from ASCLEPIOS I and II studies has demonstrated that ofatumu...

Jiuzhou Pharmaceutical to Buy Novartis API Manufacturing Facility

Zhejiang Jiuzhou Pharmaceutical has entered into a contractual commitment for the purchase of Suzhou Novartis Pharmaceutical Technology (SNPT), an API manufacturing facility in Changshu Economic Techn...

Novartis Inhaler Become First Device to Be Certified Under New EU Medical Devices Regulation

BSI’s UK notified body announced Wednesday that the Novartis Concept1 inhaler is the first device to be certified under the new EU Medical Devices Regulation (MDR). While previously classified as a...

Data Confirm Efficacy and Safety of Novartis’ Aimovig®

migraine
Novartis data confirm long-term efficacy and safety of Aimovig® for majority of patients with episodic migraine. The 5-year open-label treatment period (OLTP) examines...

Novartis and BenevolentAI to Search New Uses for Oncology Drugs

novartis
The Artificial Intelligence (AI)-based drug development firm BenevolentAI has signed an agreement with Novartis to find potential new uses for oncology drugs already in its pipeline. UK-based Benev...

IFM and Novartis Sign $840m Collaboration and Option Deal

IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, announced that IFM Due, an IFM subsidiary co...

Investigational Lung Cancer Therapy Capmatinib Granted FDA Breakthrough Therapy Designation

Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer. "We are pleased to a...